MENU

3 growth stocks that will benefit from a lower Australian dollar

The Australian dollar has fallen 7% in 2018 to 72.60 U.S. cents against a background of rising American interest rates trying to cool a surging economy. With more rate hikes from the Federal Reserve expected to occur over the next couple of years, investors could see further weakness in the Australian dollar.

A falling Australian dollar does present an opportunity for Australian based investors to profit by investing in American equities directly, or alternatively in ASX listed companies that generate a significant amount of earnings in the United States.

A lower Australian dollar makes the offshore earnings of Australian companies more valuable when they are converted back into the local currency. With that in mind, here are 3 growth stocks that would benefit from a declining Australian dollar.

Appen Ltd (ASX: APX)

Appen develops high-quality human annotated datasets that are used for machine learning and artificial intelligence. Around 88% of Appen’s revenue was derived in the United States for the first half of FY18. The company has guided for full-year underlying EBITDA to be in the range of $54 million to $59 million at an AUD/USD exchange rate of 80 cents. Appen is projected to grow earnings in FY19 by 30% and following the recent sell-off is currently trading at 31 times FY19 earnings.

Aristocrat Leisure Limited (ASX: ALL)

Aristocrat is expected to see an increase in U.S. earnings following the purchases of Big Fish Games and Plarium as it grows its presence in the mobile gaming space. The acquisitions are boosting the company’s recurring earnings and reduce the volatility of the poker machine replacement cycle’s impact on overall earnings. Approximately two-thirds of Aristocrat’s earnings are derived in the U.S. The company is projected to grow earnings by 19% to $1.40 per share in FY19, which prices the stock at a reasonable forward valuation multiple of 20.

ResMed Inc (ASX: RMD)

Sleep treatment specialist ResMed (listed as RESMED/IDR UNRESTR on Google Finance) is the market leader in its industry. The company posted another solid quarterly in August with revenue up 12% to US$624 million and Non-Gaap diluted earnings per share growing 23% to US$0.95. Shareholders of the Australian listed scrip stand to benefit from a lower Australian currency as ResMed’s ASX listing represents a 1/10th interest in the NYSE scrip. Consensus estimates are forecasting ResMed to grow earnings by 5% in FY19 to US$3.69 per share, which prices the stock on a multiple of 31 at current prices.

Earlier this year, millions of Australians set alarms and watched the world's biggest sporting event, the World Cup, play out. But did you know there was another Australian representative quietly succeeding as the world watched?

It's the start-up who have positioned themselves as the global leader in sports analytics. Motley Fool's resident tech expert has already upgraded the recommendation of this company's stock to a rating of simply "Buy More".

Click here to access this share. It's completely FREE!

Motley Fool contributor Tim Katavic owns shares of Appen Ltd and Aristocrat Leisure Limited. The Motley Fool Australia owns shares of Appen Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.